Company database
Curetis GmbH
Curetis N.V. is a commercial-stage molecular diagnostics company with principal place of business located in Holzgerlingen, Germany. On November 11, 2015, Curetis N.V. has been successfully listed on Euronext Amsterdam and Euronext Brussels under the ticker symbol “CURE”, raising EUR 44.3 Mio through its IPO.
Founded in 2007, Curetis focuses on simple-to-use, accurate and rapid solutions for diagnosing infectious diseases in critically ill, hospitalized patients. To this end, Curetis has developed the highly-automated sample- to-answer molecular diagnostics platform Unyvero, which makes diagnostic test results available within a few hours compared to time frames ranging between 24 hours and several weeks by conventional diagnostic approaches. The broad syndromic test panels of the Unyvero Cartridges enable a timely detection of a wide variety of relevant pathogens and antibiotic resistance mechanisms.
Current applications target severe cases of pneumonia, implant and tissue infections; and blood culture infections. An application for intra-abdominal infections and a cartridge for sepsis host response are under develop- ment. Curetis plans to continously expand its product pipeline by new Unyvero Cartridges.
Biotech Companies, Medtech Companies, In-vitro Diagnostics, DNA/RNA, Point-of-Care Testing, Diagnostics
Further information on the websites of BIOPRO Baden-Württemberg:
